Chemotherapy-Induced Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major chemotherapy-induced neutropenia markets reached a value of US$ 371.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 455.7 Million by 2034, exhibiting a growth rate (CAGR) of 1.88% during 2024-2034.
The chemotherapy-induced neutropenia market has been comprehensively analyzed in IMARC's new report titled "Chemotherapy-Induced Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chemotherapy-induced neutropenia refers to a serious consequence of cancer chemotherapies, in which the number of neutrophils in the blood drops below a healthy level. This loss of neutrophils results in the disruption of immune defense mechanisms and enhances the likelihood of infections. The common symptoms associated with this ailment include fever, chills, sores in the mouth, cough, difficulty breathing, abdominal or rectal pain, etc. In some cases, patients suffering from the disease may also experience diarrhea, swollen lymph nodes, and urinary symptoms, like burning urination with urgency and frequency. Diagnosing this ailment is typically based on a review of underlying symptoms, patient’s medical history, and laboratory studies. The healthcare professionals may also perform a complete blood count to determine the absolute neutrophil count of the patient. In some cases, additional testing may be utilized to evaluate the underlying cause of chemotherapy-induced neutropenia. This may include a biopsy, in which a sample of the bone marrow is examined under a microscope to identify abnormalities associated with the indications and confirm a diagnosis.
The escalating utilization of chemotherapeutic drugs for cancer treatment, which can cause damage to healthy neutrophils and the bone marrow that produces white blood cells, is primarily driving the chemotherapy-induced neutropenia market. Moreover, the widespread adoption of effective drugs, such as granulocyte colony-stimulating factors to boost neutrophil production and help protect against infection, is also bolstering the market growth. In addition to this, the inflating application of disease diagnostic tools, such as a bone marrow aspiration test to measure if the bone marrow is healthy and producing normal amounts of blood cells, is acting as another significant growth-inducing factor. Furthermore, numerous key players are making extensive investments in R&D activities to launch cost-effective injectable treatment alternatives due to quicker onset of action and faster symptom relief. This, in turn, is also creating a positive outlook for the market. Additionally, the emerging popularity of pegfilgrastim solutions for treating the ailment, since it can significantly increase peripheral blood neutrophil counts and has low renal clearance, is further expected to drive the chemotherapy-induced neutropenia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chemotherapy-induced neutropenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chemotherapy-induced neutropenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chemotherapy-induced neutropenia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chemotherapy-induced neutropenia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chemotherapy-induced neutropenia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chemotherapy-induced neutropenia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chemotherapy-induced neutropenia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chemotherapy-induced neutropenia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chemotherapy-induced neutropenia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of chemotherapy-induced neutropenia across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of chemotherapy-induced neutropenia by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of chemotherapy-induced neutropenia by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with chemotherapy-induced neutropenia across the seven major markets?
What is the size of the chemotherapy-induced neutropenia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (?2024-2034?) across the seven major markets?
What are the key factors driving the epidemiological trend of chemotherapy-induced neutropenia?
What will be the growth rate of patients across the seven major markets?
Chemotherapy-Induced Neutropenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chemotherapy-induced neutropenia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chemotherapy-induced neutropenia market?
What are the key regulatory events related to the chemotherapy-induced neutropenia market?
What is the structure of clinical trial landscape by status related to the chemotherapy-induced neutropenia market?
What is the structure of clinical trial landscape by phase related to the chemotherapy-induced neutropenia market?
What is the structure of clinical trial landscape by route of administration related to the chemotherapy-induced neutropenia market?
The chemotherapy-induced neutropenia market has been comprehensively analyzed in IMARC's new report titled "Chemotherapy-Induced Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chemotherapy-induced neutropenia refers to a serious consequence of cancer chemotherapies, in which the number of neutrophils in the blood drops below a healthy level. This loss of neutrophils results in the disruption of immune defense mechanisms and enhances the likelihood of infections. The common symptoms associated with this ailment include fever, chills, sores in the mouth, cough, difficulty breathing, abdominal or rectal pain, etc. In some cases, patients suffering from the disease may also experience diarrhea, swollen lymph nodes, and urinary symptoms, like burning urination with urgency and frequency. Diagnosing this ailment is typically based on a review of underlying symptoms, patient’s medical history, and laboratory studies. The healthcare professionals may also perform a complete blood count to determine the absolute neutrophil count of the patient. In some cases, additional testing may be utilized to evaluate the underlying cause of chemotherapy-induced neutropenia. This may include a biopsy, in which a sample of the bone marrow is examined under a microscope to identify abnormalities associated with the indications and confirm a diagnosis.
The escalating utilization of chemotherapeutic drugs for cancer treatment, which can cause damage to healthy neutrophils and the bone marrow that produces white blood cells, is primarily driving the chemotherapy-induced neutropenia market. Moreover, the widespread adoption of effective drugs, such as granulocyte colony-stimulating factors to boost neutrophil production and help protect against infection, is also bolstering the market growth. In addition to this, the inflating application of disease diagnostic tools, such as a bone marrow aspiration test to measure if the bone marrow is healthy and producing normal amounts of blood cells, is acting as another significant growth-inducing factor. Furthermore, numerous key players are making extensive investments in R&D activities to launch cost-effective injectable treatment alternatives due to quicker onset of action and faster symptom relief. This, in turn, is also creating a positive outlook for the market. Additionally, the emerging popularity of pegfilgrastim solutions for treating the ailment, since it can significantly increase peripheral blood neutrophil counts and has low renal clearance, is further expected to drive the chemotherapy-induced neutropenia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chemotherapy-induced neutropenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chemotherapy-induced neutropenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chemotherapy-induced neutropenia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chemotherapy-induced neutropenia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chemotherapy-induced neutropenia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chemotherapy-induced neutropenia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chemotherapy-induced neutropenia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chemotherapy-induced neutropenia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chemotherapy-induced neutropenia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of chemotherapy-induced neutropenia across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of chemotherapy-induced neutropenia by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of chemotherapy-induced neutropenia by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with chemotherapy-induced neutropenia across the seven major markets?
What is the size of the chemotherapy-induced neutropenia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (?2024-2034?) across the seven major markets?
What are the key factors driving the epidemiological trend of chemotherapy-induced neutropenia?
What will be the growth rate of patients across the seven major markets?
Chemotherapy-Induced Neutropenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chemotherapy-induced neutropenia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chemotherapy-induced neutropenia market?
What are the key regulatory events related to the chemotherapy-induced neutropenia market?
What is the structure of clinical trial landscape by status related to the chemotherapy-induced neutropenia market?
What is the structure of clinical trial landscape by phase related to the chemotherapy-induced neutropenia market?
What is the structure of clinical trial landscape by route of administration related to the chemotherapy-induced neutropenia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHEMOTHERAPY-INDUCED NEUTROPENIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (?2024-2034?)
4.4 Market Overview (2018-2023) and Forecast (?2024-2034?)
4.5 Competitive Intelligence
5 CHEMOTHERAPY-INDUCED NEUTROPENIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHEMOTHERAPY-INDUCED NEUTROPENIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (?2024-2034?)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 CHEMOTHERAPY-INDUCED NEUTROPENIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHEMOTHERAPY-INDUCED NEUTROPENIA - UNMET NEEDS
10 CHEMOTHERAPY-INDUCED NEUTROPENIA - KEY ENDPOINTS OF TREATMENT
11 CHEMOTHERAPY-INDUCED NEUTROPENIA - MARKETED PRODUCTS
11.1 List of Chemotherapy-Induced Neutropenia Marketed Drugs Across the Top 7 Markets
11.1.1 Neupogen (Filgrastim) - Amgen/Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rolvedon (Eflapegrastim) - Hanmi Pharmaceutical/Spectrum Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Neulasta (Pegfilgrastim) - Amgen/Kyowa Kirin
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHEMOTHERAPY-INDUCED NEUTROPENIA - PIPELINE DRUGS
12.1 List of Chemotherapy-Induced Neutropenia Pipeline Drugs Across the Top 7 Markets
12.1.1 Plinabulin - BeyondSpring Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 EC-18 - Enzychem Lifesciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 myelo001- Myelo Therapeutics GmbH
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Plinabulin- BeyondSpring Pharmaceuticals Inc.
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHEMOTHERAPY-INDUCED NEUTROPENIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHEMOTHERAPY-INDUCED NEUTROPENIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHEMOTHERAPY-INDUCED NEUTROPENIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chemotherapy-Induced Neutropenia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (?2024-2034?)
15.2.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (?2024-2034?)
15.3 Market Scenario - United States
15.3.1 Chemotherapy-Induced Neutropenia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (?2024-2034?)
15.3.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (?2024-2034?)
15.3.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chemotherapy-Induced Neutropenia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (?2024-2034?)
15.4.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (?2024-2034?)
15.4.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chemotherapy-Induced Neutropenia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (?2024-2034?)
15.5.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (?2024-2034?)
15.5.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chemotherapy-Induced Neutropenia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (?2024-2034?)
15.6.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (?2024-2034?)
15.6.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chemotherapy-Induced Neutropenia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (?2024-2034?)
15.7.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (?2024-2034?)
15.7.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chemotherapy-Induced Neutropenia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (?2024-2034?)
15.8.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (?2024-2034?)
15.8.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chemotherapy-Induced Neutropenia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (?2024-2034?)
15.9.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (?2024-2034?)
15.9.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
16 CHEMOTHERAPY-INDUCED NEUTROPENIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHEMOTHERAPY-INDUCED NEUTROPENIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHEMOTHERAPY-INDUCED NEUTROPENIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHEMOTHERAPY-INDUCED NEUTROPENIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (?2024-2034?)
4.4 Market Overview (2018-2023) and Forecast (?2024-2034?)
4.5 Competitive Intelligence
5 CHEMOTHERAPY-INDUCED NEUTROPENIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHEMOTHERAPY-INDUCED NEUTROPENIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (?2024-2034?)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 CHEMOTHERAPY-INDUCED NEUTROPENIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHEMOTHERAPY-INDUCED NEUTROPENIA - UNMET NEEDS
10 CHEMOTHERAPY-INDUCED NEUTROPENIA - KEY ENDPOINTS OF TREATMENT
11 CHEMOTHERAPY-INDUCED NEUTROPENIA - MARKETED PRODUCTS
11.1 List of Chemotherapy-Induced Neutropenia Marketed Drugs Across the Top 7 Markets
11.1.1 Neupogen (Filgrastim) - Amgen/Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rolvedon (Eflapegrastim) - Hanmi Pharmaceutical/Spectrum Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Neulasta (Pegfilgrastim) - Amgen/Kyowa Kirin
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHEMOTHERAPY-INDUCED NEUTROPENIA - PIPELINE DRUGS
12.1 List of Chemotherapy-Induced Neutropenia Pipeline Drugs Across the Top 7 Markets
12.1.1 Plinabulin - BeyondSpring Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 EC-18 - Enzychem Lifesciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 myelo001- Myelo Therapeutics GmbH
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Plinabulin- BeyondSpring Pharmaceuticals Inc.
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHEMOTHERAPY-INDUCED NEUTROPENIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHEMOTHERAPY-INDUCED NEUTROPENIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHEMOTHERAPY-INDUCED NEUTROPENIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chemotherapy-Induced Neutropenia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (?2024-2034?)
15.2.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (?2024-2034?)
15.3 Market Scenario - United States
15.3.1 Chemotherapy-Induced Neutropenia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (?2024-2034?)
15.3.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (?2024-2034?)
15.3.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chemotherapy-Induced Neutropenia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (?2024-2034?)
15.4.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (?2024-2034?)
15.4.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chemotherapy-Induced Neutropenia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (?2024-2034?)
15.5.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (?2024-2034?)
15.5.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chemotherapy-Induced Neutropenia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (?2024-2034?)
15.6.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (?2024-2034?)
15.6.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chemotherapy-Induced Neutropenia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (?2024-2034?)
15.7.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (?2024-2034?)
15.7.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chemotherapy-Induced Neutropenia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (?2024-2034?)
15.8.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (?2024-2034?)
15.8.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chemotherapy-Induced Neutropenia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (?2024-2034?)
15.9.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (?2024-2034?)
15.9.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
16 CHEMOTHERAPY-INDUCED NEUTROPENIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHEMOTHERAPY-INDUCED NEUTROPENIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHEMOTHERAPY-INDUCED NEUTROPENIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
